Istradefylline improves not only motor symptoms but also sleep disturbance, daytime sleepiness, and QOL of Parkinson’s disease patients.
Objective: This study analyzed the clinical effectiveness of istradefylline in terms of sleep disturbance in Parkinson’s disease (PD) patients. Background: A selective adenosine A2A receptor…Caffeine as a Treatment for Parkinson’s Disease: A Randomized Controlled Trial (CafePD)
Objective: To assess the effects of caffeine on patients with Parkinson's disease. Background: Multiple studies have linked use of caffeine, an adenosine antagonist, to a…Istradefylline and Preladenant as adjuvant therapies for Patients with Parkinson’s disease
Objective: The aim of this meta-analysis is to synthesize evidence about the efficacy of the adenosine receptor antagonists (Istradefylline and Preladenant) for patients with Parkinson’s…Anxiolytic-like activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002) in rodent models of anxiety
Objective: The aim of this study was to assess the anxiolytic effects of istradefylline (KW-6002), an adenosine A2A receptor antagonist, in naive and anxiety-prone animals…Strategies to improve drug development efficiency through regulatory interactions, minimizing the placebo effect and improving data integrity within a phase 3 study of tozadenant in Parkinson’s disease patients with motor fluctuations (TOZ-PD)
Objective: To identify and implement strategies to improve the efficiency of drug development in Phase 3 studies. Background: Conducting global clinical trials can be challenging,…Regional differences in the results of a phase 2b study of tozadenant in Parkinson’s disease patients with motor fluctuations
Objective: To assess how the efficacy of tozadenant differed by region in a randomized, double-blind, placebo-controlled trial of Parkinson's disease patients with motor fluctuations. Background:…Detailed evaluation of dyskinesias using multiple endpoints in a randomized, placebo-controlled trial of Parkinson’s disease patients with motor fluctuations
Objective: To analyze all dyskinesia data from a Phase 2b trial of fluctuating Parkinson patients in order to understand the overall impact a study drug…Adenosine A2A receptor antagonist istradefylline might have efficacy to fatigue and depression in some patients of Parkinson’s disease
Objective: To evaluate the efficacy of istradefylline, a selective adenosine A2A receptor antagonist, for fatigue and depression in Parkinson's disease (PD) patients. Background: Istradefylline is…Efficacy of long-term treatment with istradefylline and analysis of the expression of A2A receptor protein and post-transcriptional DNA methylation
Objective: To evaluate the pharmacological properties of Adenosine A2A receptor antagonist, istradefylline (IST), and analyze A2AR protein levels of peripheral lymphocytes and the frequency of…Differences between responders and non-responders of Istradefylline for the wearing off in Parkinson’s disease
Objective: Istradefylline is a selective antagonist of adenosine A2A receptor and was approved first in Japan for Parkinson's disease (PD) patients with by symptoms of…